We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.31%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.3B
AUM Growth
-$2.36B
Cap. Flow
-$405M
Cap. Flow %
-2.65%
Top 10 Hldgs %
84.69%
Holding
128
New
12
Increased
7
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$36M
2
AKRO
Akero Therapeutics
AKRO
+$34.4M
3
VERU icon
Veru
VERU
+$23.2M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$22.8M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$21.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$311M
2
INSM icon
Insmed
INSM
+$51.2M
3
LEGN icon
Legend Biotech
LEGN
+$47.1M
4
KRYS icon
Krystal Biotech
KRYS
+$27.9M
5
PACB icon
Pacific Biosciences
PACB
+$24.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATYR
101
aTyr Pharma
ATYR
$46.9M
$604K ﹤0.01%
201,361
-173,034
-46% -$580K
TARA icon
102
Protara Therapeutics
TARA
$215M
$591K ﹤0.01%
199,671
– –
KZR
103
DELISTED
Kezar Life Sciences
KZR
$533K ﹤0.01%
6,195
– –
CYPH
104
Cypherpunk Technologies Inc
CYPH
$63.7M
$493K ﹤0.01%
55,971
– –
CABA icon
105
Cabaletta Bio
CABA
$427M
$430K ﹤0.01%
662,063
– –
INSM icon
106
Insmed
INSM
$22.3B
$430K ﹤0.01%
19,950
-2,136,051
-99% -$51.2M
FHTX icon
107
Foghorn Therapeutics
FHTX
$279M
$386K ﹤0.01%
45,027
– –
GTH
108
DELISTED
Genetron Holdings Limited ADS
GTH
$356K ﹤0.01%
151,769
– –
VINC
109
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$333K ﹤0.01%
12,069
– –
SERA icon
110
Sera Prognostics
SERA
$83.8M
$322K ﹤0.01%
201,562
– –
BLCM
111
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$299K ﹤0.01%
249,123
– –
SRZNW icon
112
Surrozen Inc Warrant
SRZNW
$36.6K
$154K ﹤0.01%
833,333
– –
LOGC
113
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$38K ﹤0.01%
139,105
-312,373
-69% -$124K
BCAB icon
114
BioAtla
BCAB
$5.38M
– –
-16,500
Closed -$2.35M
BNR
115
Burning Rock Biotech
BNR
$93.9M
– –
-20,913
Closed -$609K
CNTA
116
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,127,273
Closed -$5.49M
HRMY icon
117
Harmony Biosciences
HRMY
$2.07B
– –
-123,600
Closed -$6.03M
INZY
118
DELISTED
Inozyme Pharma
INZY
– –
-106,999
Closed -$510K
LEGN icon
119
Legend Biotech
LEGN
$3.65B
– –
-856,658
Closed -$47.1M
MRUS
120
DELISTED
Merus
MRUS
– –
-995,397
Closed -$22.5M
PASG icon
121
Passage Bio
PASG
$14.6M
– –
-5,858
Closed -$276K
NEXI
122
DELISTED
NexImmune, Inc. Common Stock
NEXI
– –
-800
Closed -$32K
NGM
123
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-55,294
Closed -$709K
KRTX
124
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-69,966
Closed -$8.85M
EPZM
125
DELISTED
Epizyme, Inc
EPZM
– –
-1,000,000
Closed -$1.47M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Baker Bros. Advisors held 128 positions worth $15.3B, down 13% from $17.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2022 filing shows 12 new, 7 increased, 17 reduced and 13 closed positions. Its largest new stake was Veru: 160,958 shares worth $18.5M. The largest sale was argenx, an estimated $311M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2022 buy was Veru: 160,958 shares worth $18.5M.
  • Baker Bros. Advisors added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $36M increase.
  • Baker Bros. Advisors's biggest Q3 2022 reduction was argenx, cutting an estimated $311M.
  • Baker Bros. Advisors fully exited Legend Biotech in Q3 2022, selling an estimated $47.1M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.3B portfolio in Q3 2022.
  • Baker Bros. Advisors opened 12 new positions and closed 13 in Q3 2022.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $15.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.